These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29491307)

  • 1. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
    Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
    Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 3. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
    Liakakos T; Roukos DH
    Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
    [No Abstract]   [Full Text] [Related]  

  • 8. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
    Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C
    Intern Med; 2016; 55(6):629-34. PubMed ID: 26984080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
    Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
    Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.
    Gilabert M; Rho YS; Kavan P
    Oncology; 2017; 92(3):170-172. PubMed ID: 27838688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
    Williams C; Walther M
    ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastroenterological manifestations of von Hippel-Lindau disease - a case report].
    Koniusz J; Dąbkowski K; Buczek K; Gomółka A; Starzyńska T
    Pol Merkur Lekarski; 2017 Aug; 43(254):66-68. PubMed ID: 28875972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease.
    Corleto VD; Cotesta D; Petramala L; Panzuto F; Pagnini C; Masoni L; Verrienti A; Delle Fave G; Filetti S; Letizia C
    JOP; 2009 Sep; 10(5):562-5. PubMed ID: 19734639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pancreatic neuroendocrine tumors and von Hippel-Lindau disease].
    Musso C; Paraf F; Petit B; Archambeaud-Mouveroux F; Valleix D; Labrousse F
    Ann Pathol; 2000 Mar; 20(2):130-3. PubMed ID: 10740008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease.
    Tamura K; Nishimori I; Ito T; Yamasaki I; Igarashi H; Shuin T
    World J Gastroenterol; 2010 Sep; 16(36):4515-8. PubMed ID: 20857520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic mixed serous neuroendocrine neoplasm with clear cells leading to diagnosis of von Hippel Lindau disease.
    Kakkar A; Sharma MC; Yadav R; Panwar R; Mathur SR; Iyer VK; Sahni P
    Pathol Res Pract; 2016 Aug; 212(8):747-50. PubMed ID: 27161305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.